SCHEDULE: T. Rowe Price Reports Stake in Bicara Therapeutics

T. Rowe Price Investment Management, Inc. has updated its beneficial ownership filing for Bicara Therapeutics Inc., now holding 4.2% of the company's common stock.

Summary

• T. Rowe Price Investment Management, Inc. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Bicara Therapeutics Inc. common stock.
• As of September 30, 2026, T. Rowe Price Investment Management, Inc. beneficially owns 2,804,772 shares of Bicara Therapeutics Inc. common stock.
• This represents 4.2% of the class of securities outstanding.
• The filing indicates sole voting power over 2,798,430 shares and sole dispositive power over 2,804,772 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage without significant new strategic or financial information.

Positives

• T. Rowe Price Investment Management, Inc., a significant institutional investor, has increased its stake or maintained its position, indicating continued confidence in Bicara Therapeutics.
• The filing clearly states the exact number of shares beneficially owned and the percentage of the class, providing transparency for investors.

Negatives

• The filing does not provide any new financial results, strategic updates, or forward-looking guidance from Bicara Therapeutics itself, limiting insight into the company's performance.
• The nature of the filing as a Schedule 13G suggests it is a routine disclosure of beneficial ownership rather than a response to a specific event.

Risks

• The filing does not explicitly mention any new risks or changes to existing risk factors for Bicara Therapeutics.
• The primary risk associated with this filing is the lack of detailed operational or financial information, making it difficult to assess the underlying reasons for T. Rowe Price's investment level.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Bicara Therapeutics. It solely reports on the beneficial ownership of T. Rowe Price Investment Management, Inc.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

StockSavvy.ai notes that institutional investor filings like this Schedule 13G are common in the biotechnology sector as companies advance through clinical trials and seek funding. The 4.2% stake by T. Rowe Price suggests a significant, but not controlling, interest, typical for an asset manager in a publicly traded company.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's holdings, potentially influencing market perception.
• Management: Awareness of T. Rowe Price's substantial stake may influence strategic decisions and communication with the investment community.

Next Steps

• T. Rowe Price Investment Management, Inc. will continue to monitor its beneficial ownership of Bicara Therapeutics Inc. and file amendments as required by SEC regulations.

Key Dates

Keywords

Bicara Therapeutics, T. Rowe Price, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, Institutional Investor